Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03090386 · ClinicalTrials.gov registry record
Evaluation of Cognitive-Communication Deficits Following Treatment of Primary Brain Tumor Patients
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 30
- Enrollment target
NCT03090386: Completed study, sponsored by Mayo Clinic.
NCT03090386 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03090386 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This study is to evaluate which cognitive-linguistic symptoms are most commonly experienced following brain tumor treatment. Cognitive surveys will be administered after treatment of primary brain tumor cancer.
Primary Outcome
Survey is completed at time of consent
Interventions
- OTHER Cognitive Surveys
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-02-25 |
| Est. Completion | 2020-11-15 |
What the finished NCT03090386 record still lists
NCT03090386 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Cognitive Surveys is the first listed.
NCT03090386 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03090386 about?
NCT03090386 is a clinical study titled "Evaluation of Cognitive-Communication Deficits Following Treatment of Primary Brain Tumor Patients". This study is to evaluate which cognitive-linguistic symptoms are most commonly experienced following brain tumor treatment. Cognitive surveys will be administered after treatment of primary brain tumor cancer.
What is the current status of trial NCT03090386?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2017-02-25. Estimated completion is 2020-11-15.
What interventions are being tested in trial NCT03090386?
The interventions under investigation include: Cognitive Surveys (OTHER).
Who is sponsoring clinical trial NCT03090386?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI